The discovery of AVIL as a bona fide oncogene in glioblastoma

Zhongqiu Xie; Hui Li

doi:10.1080/23723556.2020.1804309

The discovery of AVIL as a bona fide oncogene in glioblastoma

Mol Cell Oncol. 2020 Sep 25;7(6):1804309. doi: 10.1080/23723556.2020.1804309. eCollection 2020.

Authors

Zhongqiu Xie¹, Hui Li^{1

2}

Affiliations

¹ Department of Pathology, School of Medicine, University of Virginia, Charlottesville, VA, USA.
² Department of Biochemistry and Molecular Genetics, School of Medicine, University of Virginia, Charlottesville, VA, USA.

Abstract

Our work in rhabdomyosarcoma led us to the discovery of a novel oncogene, Advillin (AVIL) in glioblastoma. Multiple lines of evidence support that AVIL is an Achilles heel of glioblastoma, with its specific targeting potentially an effective treatment approach for the disease. A new signaling axis was also established.

Keywords: AVIL; glioblastoma; oncogene addiction; rhabdomyosarcoma.

Abstract

Grants and funding